Table 1.
Liver disease | Major TNF effect |
---|---|
APAP-induced liver damage | Tissue repair [45] |
Alcoholic liver disease (ALD) | None [52] |
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) |
Increased serum levels and hepatic expression of TNF and TNFR1, correlating with disease activity in NASH patients [64–66], TNFR1-dependent attenuation of insulin resistance and liver injury in a mouse model [68], Normalisation of liver biochemistry in a NASH patient treated with adalimumab for co-existing RA [69] |
Viral hepatitis | |
HBV | Induction of cell death in HBV-infected hepatocytes, NFκB-dependent blockade of HBV replication [75, 83, 85] |
HCV | Induction of apoptosis in HCV-infected Huh-7.5 cells [77] |
Autoimmune liver disease | |
AIH |
TNF polymorphism associated with type 1 AIH susceptibility [93], Successful treatment of AIH with infliximab [6] |
PBC |
Pathway analysis provided evidence for enhanced TNF signalling in PBC pathogenesis [87], Stabilisation of liver function in PBC patients treated with TNF antagonists for co-existing RA [90, 91] |
PSC |
High expression levels of TNF in innate-like CD4+ T cells from PSC patients [113], Moderate effectiveness of anti-TNF therapies in PSC/IBD patients [114, 115] |
AIH, autoimmune hepatitis; APAP, acetaminophen; HBV, hepatitis B virus; HCV, hepatitis C virus; IBD, inflammatory bowel disease; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; RA, rheumatoid arthritis; TNF, tumour necrosis factor; TNFR, TNF receptor